{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Eric Fischer"}, {"accession": "MS:1000589", "name": "contact email", "value": "eric_fischer@dfci.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Dana-Farber Cancer Institute"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Eric Fischer"}, {"accession": "MS:1000589", "name": "contact email", "value": "eric_fischer@dfci.harvard.edu"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA"}]}], "datasetFiles": [{"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1628.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1629.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1630.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1631.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1632.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1633.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1634.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1635.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1636.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1637.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1638.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1639.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1640.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1641.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1642.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1643.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1644.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1645.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1646.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1647.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1648.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1649.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1650.raw"}, {"accession": "PRIDE:0000404", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/esf_1651.raw"}, {"accession": "PRIDE:0000408", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346/wp-esf_085_f24_20181023.pep.xml"}], "description": "Targeted protein degradation (TPD) has emerged as a promising new drug development paradigm. We leveraged this strategy to develop a new class of small molecule antivirals that induce proteasomal degradation of viral proteins. Telaprevir, a \u2018reversible-covalent\u2019 inhibitor that binds to the hepatitis C virus (HCV) protease active site was conjugated to ligands that recruit the CRL4CRBN ligase complex, yielding compounds that can both inhibit and induce the degradation of the HCV NS3/4A protease. We developed an optimized degrader, DGY-08-097, that potently inhibits HCV in a cellular infection model and demonstrate that protein degradation contributes to its antiviral activity. Finally, we show that this new class of antiviral agents can overcome viral variants that confer resistance to traditional enzymatic inhibitors such as telaprevir. Overall, our work provides proof-of-concept that targeted protein degradation may provide a new paradigm for the development of antivirals with superior resistance profiles.", "fullDatasetLinks": [{"accession": "PRIDE:0000411", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/07/PXD014346"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD014346"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD014346"}], "instruments": [{"accession": "MS:1002732", "name": "Orbitrap Fusion Lumos"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "hcv, telaprevir, PROTAC, thalidomide, ubiquitin, crl4"}], "modifications": [{"accession": "MOD:01720", "name": "TMT6plex-126 reporter+balance reagent acylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31371704"}, {"accession": "PRIDE:0000400", "name": "Reference", "value": "de Wispelaere M, Du G, Donovan KA, Zhang T, Eleuteri NA, Yuan JC, Kalabathula J, Nowak RP, Fischer ES, Gray NS, Yang PL. Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. Nat Commun. 2019 10(1):3468"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Small Molecule Degraders of the Hepatitis C Virus Protease Reduce Susceptibility to Resistance Mutations"}